These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 39204319)

  • 21. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-cytokine fusion proteins for the therapy of cancer.
    Helguera G; Penichet ML
    Methods Mol Med; 2005; 109():347-74. PubMed ID: 15585931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of cancer by IL-12-based cytokine combinations.
    Weiss JM; Subleski JJ; Wigginton JM; Wiltrout RH
    Expert Opin Biol Ther; 2007 Nov; 7(11):1705-21. PubMed ID: 17961093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1.
    Lees CJ; Apostolopoulos V; Acres B; Ong CS; Popovski V; McKenzie IF
    Cancer Immunol Immunother; 2000 Feb; 48(11):644-52. PubMed ID: 10663612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The present and future of immunocytokines for cancer treatment.
    Gout DY; Groen LS; van Egmond M
    Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokines in the Treatment of Cancer.
    Conlon KC; Miljkovic MD; Waldmann TA
    J Interferon Cytokine Res; 2019 Jan; 39(1):6-21. PubMed ID: 29889594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical and clinical development of immunocytokines.
    Sondel PM; Hank JA; Gan J; Neal Z; Albertini MR
    Curr Opin Investig Drugs; 2003 Jun; 4(6):696-700. PubMed ID: 12901228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunocytokines: a promising approach to cancer immunotherapy.
    Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
    Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.
    Bootz F; Neri D
    Drug Discov Today; 2016 Jan; 21(1):180-189. PubMed ID: 26526566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses.
    Viola NT; Glassbrook JE; Kalluri JR; Hackett JB; Wicker MN; Sternberg J; Gibson HM
    Front Immunol; 2022; 13():870110. PubMed ID: 35634303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.
    Zheng X; Wu Y; Bi J; Huang Y; Cheng Y; Li Y; Wu Y; Cao G; Tian Z
    Cell Mol Immunol; 2022 Feb; 19(2):192-209. PubMed ID: 35043005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted cytokines for cancer immunotherapy.
    Lode HN; Reisfeld RA
    Immunol Res; 2000; 21(2-3):279-88. PubMed ID: 10852128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.
    Kumar A; Taghi Khani A; Sanchez Ortiz A; Swaminathan S
    Front Immunol; 2022; 13():901277. PubMed ID: 35865534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.